Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B

Kavakli K 1 , Smith L 2 , Kuliczkowski K 3 , Korth-Bradley J 2 , You CW 4 , Fuiman J 2 Show all authors , Zupančić-Šalek S 5 , Abdul Karim F 6 , Rendo P 2

Affiliations 

  • 1 Department of Pediatric Hematology, Ege University Children's Hospital, Izmir, Turkey
  • 2 Pfizer Inc, Collegeville, PA, USA
  • 3 University of Wroclaw, Wroclaw, Poland
  • 4 Eulji University, Daejeon, Korea
  • 5 University Hospital Centre Rebro, Zagreb, Croatia
  • 6 National Blood Centre in Kuala Lumpur, Kuala Lumpur, Malaysia
Haemophilia, 2016 May;22(3):381-8.
PMID: 26823276 DOI: 10.1111/hae.12878

Abstract

Limited data are available on optimal prophylaxis regimens of factor IX (FIX) replacements for patients with haemophilia B.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications